Quick Answer
Akari Therapeutics Plc reported Operating Income of -$17.27 million for fiscal year 2025.
Akari Therapeutics Plc Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$17.27M | +20.2% |
| 2024 | -$21.64M | -28.8% |
| 2023 | -$16.81M | +27.2% |
| 2022 | -$23.09M | -34.1% |
| 2021 | -$17.21M | +4.3% |
| 2020 | -$17.98M | -6.0% |
| 2019 | -$16.96M | +18.4% |
| 2018 | -$20.79M | +45.0% |
| 2017 | -$37.78M | -38.7% |
| 2016 | -$27.25M | +10.9% |
| 2015 | -$30.58M | -1493.5% |
| 2014 | -$1.92M | +46.8% |
| 2013 | -$3.61M | +1.7% |
| 2012 | -$3.67M | -63.2% |
| 2011 | -$2.25M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.40M | -153.0% | -137.4% |
| June 30, 2025 | -$3.12M | +58.1% | +11.5% |
| March 31, 2025 | -$3.52M | +41.1% | -20.4% |
| September 30, 2024 | -$2.93M | -16.8% | +60.7% |
| June 30, 2024 | -$7.45M | -61.4% | -24.4% |
| March 31, 2024 | -$5.99M | -30.4% | -138.9% |
| September 30, 2023 | -$2.51M | — | +45.7% |
| June 30, 2023 | -$4.62M | — | -0.5% |
- Akari Therapeutics Plc showed an increase of +20.2% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, Akari Therapeutics Plc’s operating income has declined by 668.8% (from -$2.25 million to -$17.27 million).
- The most recent figure is from Akari Therapeutics Plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: